Callan Family Office, LLC
Family OfficePosition in NAUT — Nautilus Biotechnology, Inc.
CIK 1938970
RADNOR, PA
Position in NAUT
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$48,563
-$52,200 QoQ
Shares Held
25,970
0.0% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#59
of 93 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAUT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Callan Family Office, LLC holds $29,170,140 across 30 Biotechnology names. NAUT ranks #23 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,789 | $7,842,869 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,138 | $6,321,448 | |
| 3 | ARGX |
Argenx SE
|
2,035 | $1,888,011 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
7,722 | $1,860,770 | |
| 5 | TECH |
BIO-TECHNE Corp
|
22,045 | $1,557,479 | |
| 6 | GMAB |
Genmab A/S
|
55,033 | $1,511,756 | |
| 7 | INCY |
Incyte Corp
|
11,538 | $1,307,947 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
3,224 | $1,019,074 |
All Filings in NAUT
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $48,563 | 25,970 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $100,763 | 25,970 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $50,641 | 25,970 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $12,531 | 14,830 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $35,448 | 48,894 | Shares | Sole | 2025-07-24 | |
| No filing history on record for this holder in this stock. | ||||||